全文获取类型
收费全文 | 4175篇 |
免费 | 155篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 181篇 |
儿科学 | 85篇 |
妇产科学 | 125篇 |
基础医学 | 608篇 |
口腔科学 | 46篇 |
临床医学 | 392篇 |
内科学 | 1115篇 |
皮肤病学 | 15篇 |
神经病学 | 264篇 |
特种医学 | 130篇 |
外科学 | 474篇 |
综合类 | 33篇 |
一般理论 | 3篇 |
预防医学 | 218篇 |
眼科学 | 72篇 |
药学 | 333篇 |
中国医学 | 2篇 |
肿瘤学 | 263篇 |
出版年
2024年 | 5篇 |
2023年 | 32篇 |
2022年 | 171篇 |
2021年 | 254篇 |
2020年 | 70篇 |
2019年 | 120篇 |
2018年 | 148篇 |
2017年 | 89篇 |
2016年 | 107篇 |
2015年 | 127篇 |
2014年 | 180篇 |
2013年 | 229篇 |
2012年 | 337篇 |
2011年 | 371篇 |
2010年 | 180篇 |
2009年 | 112篇 |
2008年 | 248篇 |
2007年 | 255篇 |
2006年 | 289篇 |
2005年 | 235篇 |
2004年 | 235篇 |
2003年 | 201篇 |
2002年 | 140篇 |
2001年 | 18篇 |
2000年 | 7篇 |
1999年 | 14篇 |
1998年 | 16篇 |
1997年 | 13篇 |
1996年 | 11篇 |
1995年 | 9篇 |
1994年 | 9篇 |
1993年 | 8篇 |
1992年 | 10篇 |
1991年 | 9篇 |
1990年 | 12篇 |
1989年 | 14篇 |
1988年 | 7篇 |
1987年 | 9篇 |
1985年 | 5篇 |
1984年 | 3篇 |
1983年 | 6篇 |
1982年 | 4篇 |
1981年 | 4篇 |
1980年 | 4篇 |
1979年 | 4篇 |
1978年 | 5篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1975年 | 6篇 |
1972年 | 3篇 |
排序方式: 共有4359条查询结果,搜索用时 0 毫秒
91.
92.
AA Toor KK Payne HM Chung RT Sabo AF Hazlett M Kmieciak K Sanford DC Williams WB Clark CH Roberts JM McCarty MH Manjili 《British journal of haematology》2012,158(6):700-711
Patients with multiple myeloma (MM) undergoing high dose therapy and autologous stem cell transplantation (SCT) remain at risk for disease progression. Induction of the expression of highly immunogenic cancer testis antigens (CTA) in malignant plasma cells in MM patients may trigger a protective immune response following SCT. We initiated a phase II clinical trial of the DNA hypomethylating agent, azacitidine (Aza) administered sequentially with lenalidomide (Rev) in patients with MM. Three cycles of Aza and Rev were administered and autologous lymphocytes were collected following the 2nd and 3rd cycles of Aza‐Rev and cryopreserved. Subsequent stem cell mobilization was followed by high‐dose melphalan and SCT. Autologous lymphocyte infusion (ALI) was performed in the second month following transplantation. Fourteen patients have completed the investigational therapy; autologous lymphocytes were collected from all of the patients. Thirteen patients have successfully completed SCT and 11 have undergone ALI. Six patients tested have demonstrated CTA up‐regulation in either unfractionated bone marrow (n = 4) or CD138+ cells (n = 2). CTA (CTAG1B)‐specific T cell response has been observed in all three patients tested and persists following SCT. Epigenetic induction of an adaptive immune response to cancer testis antigens is safe and feasible in MM patients undergoing SCT. 相似文献
93.
94.
Bielecka-Dabrowa A Mikhailidis DP Jones L Rysz J Aronow WS Banach M 《International journal of cardiology》2012,158(1):12-17
Maintenance of normal potassium (K(+)) homeostasis has become an increasingly important limiting factor in the therapy of heart failure (HF). With the application of loop diuretics and digoxin, hypokalemia has become a frequent and feared side effect of treatment. Low serum K(+) in HF may be also a marker of increased neurohormonal activity and disease progression. To gain the maximum benefit from treatment, we need to individualize drug use and carefully monitor electrolytes. Symptomatic HF patients (New York Heart Association class III-IV) should be prescribed the lowest dose of diuretic necessary to maintain euvolemia. Mild hypokalemia may be corrected by the use of aldosterone receptor antagonists such as spironolactone or eplerenone. However, a more severe hypokalemia should preferably be corrected using K(+) supplement. Serum K levels should be frequently checked and maintained between 4.0 and 5.5 mEq/l (mmol/l). 相似文献
95.
96.
Wojcik M Kuniss M Berkowitsch A Neumann T 《Revista espa?ola de cardiología》2012,65(6):584-5; author reply 585
97.
Aleksandra Bala Szczepan Iwański Jarosław Żyłkowski Maciej Jaworski Joanna Seniów Andrzej Marchel 《Neurocase》2013,19(3):331-338
Presented case report illustrates symptoms of prosopometamorphopsia (PM) and prosopagnosia, observed in the early days after the onset of a hemorrhagic stroke resulting from a complication of endovascular treatment of intracranial aneurysms and the use of anticoagulation therapy. PM is a visual disorder in which faces are perceived as distorted. The female patient described in the present study reported that faces she looked at seemed younger or older than in reality or as if they were dirty, swollen, or with a grimace. She also experienced symptoms of prosopagnosia, which is difficulty of recognizing familiar faces of people (e.g., of her husband and daughter). In the interview 6 months after the first examination, the patient reported spontaneous withdrawal of the visual disturbances. 相似文献
98.
Beata Franczyk-Skóra Anna Gluba Maciej Banach Jacek Rysz 《Archives of Medical Science》2013,9(6):1019-1027
Renal dysfunction is frequent in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Chronic kidney disease (CKD) is associated with very poor prognosis and is an independent predictor of early and late mortality and major bleeding in patients with NSTE-ACS. Patients with NSTE-ACS and CKD are still rarely treated according to guidelines. Medical registers reveal that patients with CKD are usually treated with too high doses of antithrombotics, especially anticoagulants and inhibitors of platelet glycoprotein (GP) IIb/IIIa receptors, and therefore they are more prone to bleeding. Drugs which are excreted mainly or exclusively by the kidney should be administered in a reduced dose or discontinued in patients with CKD. These drugs include enoxaparin, fondaparinux, bivalirudin, and small molecule inhibitors of GP IIb/IIIa inhibitors. In long-term treatment of patients after myocardial infarction, anti-platelet therapy, lipid-lowering therapy and β-blockers are used. Chronic kidney disease patients before qualification for coronary interventions should be carefully selected in order to avoid their use in the group of patients who could not benefit from such procedures. This paper presents schemes of non-ST and ST-segment elevation myocardial infarction treatment in CKD patients in accordance with the current recommendations of the European Society of Cardiology (ESC). 相似文献
99.
100.
Anna Szumera-Cie?kiewicz W?odzimierz T Olszewski Andrzej Tysarowski Dariusz M Kowalski Maciej G?ogowski Maciej Krzakowski Janusz A Siedlecki Micha? W?grodzki Monika Prochorec-Sobieszek 《International journal of clinical and experimental pathology》2013,6(12):2800-2812
The targeted treatment of advanced non-small-cell lung cancer (NSCLC) depends on confirmation of activating somatic EGFR mutation. The aim of the study was to evaluate the incidence of EGFR mutations in NSCLC detected in cytological and histological material and present literature review on European EGFR mutation incidence. 273 patients with confirmed NSCLC were entered into the study: 189 histological, paraffin-embedded materials, 12 fresh and 72 fixed cytological specimens. DNA was extracted from both types of material and the EGFR mutation in exons 18-21 was analyzed by direct sequencing. In addition the EGFR gene copy number in cases with sufficient histological material (110 patients) was evaluated by fluorescent in situ hybridization (FISH) technique. The percentage of EGFR somatic mutations was 10.62%. FISH positive results (amplification or high polysomy of EGFR gene) were identified in 33 patients (30.0%). The strongest clinicopathological correlation with the EGFR mutation was found for histological type (adenocarcinoma; p < 0.01), gender (females; p < 0.01) and FISH positive result (p < 0.05). This is the first, single institution study that estimates the EGFR mutation incidence in the Polish population. Cytological material recovered from fixed preparations and stained with hematoxylin and eosin showed DNA quality comparable to fresh tumor cells and histological samples. 相似文献